Whole Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 May Cause False-Positive Results in Serological Assays.
作者信息
Yamaoka Yutaro, Jeremiah Sundararaj S, Miyakawa Kei, Saji Ryo, Nishii Mototsugu, Takeuchi Ichiro, Ryo Akihide
机构信息
Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
Life Science Laboratory, Technology and Development Division, Kanto Chemical Co, Inc, Kanagawa, Japan.
出版信息
Clin Infect Dis. 2021 Apr 8;72(7):1291-1292. doi: 10.1093/cid/ciaa637.
Abstract
摘要
相似文献
1
Whole Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 May Cause False-Positive Results in Serological Assays.
Clin Infect Dis. 2021 Apr 8;72(7):1291-1292. doi: 10.1093/cid/ciaa637.
2
False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based western blot assay were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV.
Clin Vaccine Immunol. 2006 Mar;13(3):409-14. doi: 10.1128/CVI.13.3.409-414.2006.
3
False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide.
J Clin Microbiol. 2004 Dec;42(12):5885-8. doi: 10.1128/JCM.42.12.5885-5888.2004.
4
The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development.
J Virol. 2020 Jun 16;94(13). doi: 10.1128/JVI.00647-20.
5
From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes.
J Med Virol. 2020 Jun;92(6):660-666. doi: 10.1002/jmv.25754. Epub 2020 Mar 16.
6
Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.
Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8. doi: 10.1128/CDLI.11.4.665-668.2004.
7
Serological differentiation between COVID-19 and SARS infections.
Emerg Microbes Infect. 2020 Dec;9(1):1497-1505. doi: 10.1080/22221751.2020.1780951.
8
[Molecular cloning and expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid protein and its clinical application].
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Mar;19(1):64-7.
9
Antigenic cross-reactivity between the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus and polyclonal antisera of antigenic group I animal coronaviruses: implication for SARS diagnosis.
J Clin Microbiol. 2004 May;42(5):2351-2. doi: 10.1128/JCM.42.5.2351-2352.2004.
10
Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia.
J Clin Microbiol. 2005 Jul;43(7):3054-8. doi: 10.1128/JCM.43.7.3054-3058.2005.
引用本文的文献
1
Identification of undetected SARS-CoV-2 infections by clustering of Nucleocapsid antibody trajectories.
Nat Commun. 2025 May 14;16(1):4466. doi: 10.1038/s41467-025-57370-z.
2
Identification of B-Cell Linear Epitopes in the Nucleocapsid (N) Protein B-Cell Linear Epitopes Conserved among the Main SARS-CoV-2 Variants.
Viruses. 2023 Apr 6;15(4):923. doi: 10.3390/v15040923.
3
A new multiplex SARS-CoV-2 antigen microarray showed correlation of IgG, IgA, and IgM antibodies from patients with COVID-19 disease severity and maintenance of relative IgA and IgM antigen binding over time.
PLoS One. 2023 Mar 30;18(3):e0283537. doi: 10.1371/journal.pone.0283537. eCollection 2023.
4
The evaluation results of proposed antigen rapid diagnostic tests for COVID-19: some possible factors might influence.
Infection. 2023 Oct;51(5):1285-1291. doi: 10.1007/s15010-022-01975-9. Epub 2023 Jan 2.
5
Antibody tests for identification of current and past infection with SARS-CoV-2.
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
6
On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy.
Viruses. 2022 Oct 27;14(11):2378. doi: 10.3390/v14112378.
7
Association between IgG responses against the nucleocapsid proteins of alphacoronaviruses and COVID-19 severity.
Front Immunol. 2022 Sep 7;13:889836. doi: 10.3389/fimmu.2022.889836. eCollection 2022.
8
Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins.
Int J Mol Sci. 2022 Mar 10;23(6):2977. doi: 10.3390/ijms23062977.
9
Assessment of Diagnostic Specificity of Anti-SARS-CoV-2 Antibody Tests and Their Application for Monitoring of Seroconversion and Stability of Antiviral Antibody Response in Healthcare Workers in Moscow.
Microorganisms. 2022 Feb 12;10(2):429. doi: 10.3390/microorganisms10020429.
10
Antigenic properties of the SARS-CoV-2 nucleoprotein are altered by the RNA admixture.
PeerJ. 2022 Jan 7;10:e12751. doi: 10.7717/peerj.12751. eCollection 2022.
Zotero 插件